Free Trial
→ Analyst nicknamed “The Prophet” issues new warning for America (From Stansberry Research) (Ad)tc pixel Free APVO Stock Alerts

Aptevo Therapeutics (APVO) Competitors

Aptevo Therapeutics logo
$1.79 -0.01 (-0.56%)
Closing price 10/9/2026 03:55 PM Eastern
Extended Trading
$1.81 +0.02 (+1.12%)
As of 10/9/2026 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

APVO vs. BIVI, PLUR, VTGN, BLRX, and PHIO

Should you buy Aptevo Therapeutics stock or one of its competitors? Aptevo Therapeutics's main competitors and comparable companies include BioVie (BIVI), Pluri (PLUR), VistaGen Therapeutics (VTGN), BioLineRx (BLRX), and Phio Pharmaceuticals (PHIO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Aptevo Therapeutics compare to BioVie?

Aptevo Therapeutics (NASDAQ:APVO) and BioVie (NASDAQ:BIVI) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, dividends and profitability.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aptevo Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
BioVie
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Aptevo Therapeutics had 1 more articles in the media than BioVie. MarketBeat recorded 2 mentions for Aptevo Therapeutics and 1 mentions for BioVie. Aptevo Therapeutics' average media sentiment score of 0.00 equaled BioVie'saverage media sentiment score.

Company Overall Sentiment
Aptevo Therapeutics Neutral
BioVie Neutral

BioVie is trading at a lower price-to-earnings ratio than Aptevo Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aptevo TherapeuticsN/AN/A-$25.97M-$51.83N/A
BioVieN/AN/A-$22.07M-$3.15N/A

Aptevo Therapeutics has a beta of 1.67, meaning that its stock price is 67% more volatile than the broader market. Comparatively, BioVie has a beta of 0.73, meaning that its stock price is 27% less volatile than the broader market.

BioVie's return on equity of -126.02% beat Aptevo Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Aptevo TherapeuticsN/A -201.49% -119.21%
BioVie N/A -126.02%-108.88%

8.1% of Aptevo Therapeutics shares are held by institutional investors. Comparatively, 4.6% of BioVie shares are held by institutional investors. 0.4% of Aptevo Therapeutics shares are held by company insiders. Comparatively, 16.7% of BioVie shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

BioVie beats Aptevo Therapeutics on 5 of the 9 factors compared between the two stocks.

How does Aptevo Therapeutics compare to Pluri?

Aptevo Therapeutics (NASDAQ:APVO) and Pluri (NASDAQ:PLUR) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

Aptevo Therapeutics has a beta of 1.67, indicating that its share price is 67% more volatile than the broader market. Comparatively, Pluri has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market.

In the previous week, Aptevo Therapeutics and Aptevo Therapeutics both had 2 articles in the media. Aptevo Therapeutics' average media sentiment score of 1.39 beat Pluri's score of 1.25 indicating that Aptevo Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Aptevo Therapeutics Positive
Pluri Positive

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aptevo Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Pluri
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Aptevo Therapeutics has a net margin of 0.00% compared to Pluri's net margin of -2,344.59%. Pluri's return on equity of 0.00% beat Aptevo Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Aptevo TherapeuticsN/A -201.49% -119.21%
Pluri -2,344.59%N/A -82.71%

8.1% of Aptevo Therapeutics shares are owned by institutional investors. Comparatively, 16.6% of Pluri shares are owned by institutional investors. 0.4% of Aptevo Therapeutics shares are owned by insiders. Comparatively, 43.2% of Pluri shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Pluri has higher revenue and earnings than Aptevo Therapeutics. Pluri is trading at a lower price-to-earnings ratio than Aptevo Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aptevo TherapeuticsN/AN/A-$25.97M-$51.83N/A
Pluri$1.02M11.83-$23.82M-$2.45N/A

Summary

Pluri beats Aptevo Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Aptevo Therapeutics compare to VistaGen Therapeutics?

Aptevo Therapeutics (NASDAQ:APVO) and VistaGen Therapeutics (NASDAQ:VTGN) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation and dividends.

Aptevo Therapeutics has a net margin of 0.00% compared to VistaGen Therapeutics' net margin of -2,702.64%. VistaGen Therapeutics' return on equity of -152.59% beat Aptevo Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Aptevo TherapeuticsN/A -201.49% -119.21%
VistaGen Therapeutics -2,702.64%-152.59%-117.45%

VistaGen Therapeutics has a consensus price target of $0.95, indicating a potential upside of 302.37%. Given VistaGen Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe VistaGen Therapeutics is more favorable than Aptevo Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aptevo Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
VistaGen Therapeutics
1 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.80

In the previous week, Aptevo Therapeutics and Aptevo Therapeutics both had 2 articles in the media. Aptevo Therapeutics' average media sentiment score of 1.39 beat VistaGen Therapeutics' score of 1.28 indicating that Aptevo Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Aptevo Therapeutics Positive
VistaGen Therapeutics Positive

Aptevo Therapeutics has higher earnings, but lower revenue than VistaGen Therapeutics. VistaGen Therapeutics is trading at a lower price-to-earnings ratio than Aptevo Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aptevo TherapeuticsN/AN/A-$25.97M-$51.83N/A
VistaGen Therapeutics$1.27M8.25-$69.68M-$1.66N/A

8.1% of Aptevo Therapeutics shares are owned by institutional investors. Comparatively, 78.4% of VistaGen Therapeutics shares are owned by institutional investors. 0.4% of Aptevo Therapeutics shares are owned by insiders. Comparatively, 2.9% of VistaGen Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Aptevo Therapeutics has a beta of 1.67, indicating that its share price is 67% more volatile than the broader market. Comparatively, VistaGen Therapeutics has a beta of 0.33, indicating that its share price is 67% less volatile than the broader market.

Summary

VistaGen Therapeutics beats Aptevo Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Aptevo Therapeutics compare to BioLineRx?

Aptevo Therapeutics (NASDAQ:APVO) and BioLineRx (NASDAQ:BLRX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, media sentiment, institutional ownership, dividends, profitability and earnings.

Aptevo Therapeutics has a beta of 1.67, suggesting that its stock price is 67% more volatile than the broader market. Comparatively, BioLineRx has a beta of 1.61, suggesting that its stock price is 61% more volatile than the broader market.

In the previous week, BioLineRx had 1 more articles in the media than Aptevo Therapeutics. MarketBeat recorded 3 mentions for BioLineRx and 2 mentions for Aptevo Therapeutics. Aptevo Therapeutics' average media sentiment score of 0.00 equaled BioLineRx'saverage media sentiment score.

Company Overall Sentiment
Aptevo Therapeutics Neutral
BioLineRx Neutral

8.1% of Aptevo Therapeutics shares are owned by institutional investors. Comparatively, 1.6% of BioLineRx shares are owned by institutional investors. 0.4% of Aptevo Therapeutics shares are owned by company insiders. Comparatively, 1.1% of BioLineRx shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aptevo Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
BioLineRx
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

BioLineRx has higher revenue and earnings than Aptevo Therapeutics. BioLineRx is trading at a lower price-to-earnings ratio than Aptevo Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aptevo TherapeuticsN/AN/A-$25.97M-$51.83N/A
BioLineRx$1.18M9.37-$1.17M-$1.69N/A

Aptevo Therapeutics has a net margin of 0.00% compared to BioLineRx's net margin of -502.08%. BioLineRx's return on equity of -34.80% beat Aptevo Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Aptevo TherapeuticsN/A -201.49% -119.21%
BioLineRx -502.08%-34.80%-18.27%

Summary

BioLineRx beats Aptevo Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Aptevo Therapeutics compare to Phio Pharmaceuticals?

Aptevo Therapeutics (NASDAQ:APVO) and Phio Pharmaceuticals (NASDAQ:PHIO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, earnings, risk and valuation.

In the previous week, Phio Pharmaceuticals had 1 more articles in the media than Aptevo Therapeutics. MarketBeat recorded 3 mentions for Phio Pharmaceuticals and 2 mentions for Aptevo Therapeutics. Aptevo Therapeutics' average media sentiment score of 1.39 beat Phio Pharmaceuticals' score of 0.56 indicating that Aptevo Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Aptevo Therapeutics Positive
Phio Pharmaceuticals Positive

Phio Pharmaceuticals has a consensus target price of $14.00, indicating a potential upside of 1,330.32%. Given Phio Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Phio Pharmaceuticals is more favorable than Aptevo Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aptevo Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Phio Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

8.1% of Aptevo Therapeutics shares are owned by institutional investors. Comparatively, 57.3% of Phio Pharmaceuticals shares are owned by institutional investors. 0.4% of Aptevo Therapeutics shares are owned by company insiders. Comparatively, 3.5% of Phio Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Aptevo Therapeutics has a beta of 1.67, suggesting that its share price is 67% more volatile than the broader market. Comparatively, Phio Pharmaceuticals has a beta of 0.84, suggesting that its share price is 16% less volatile than the broader market.

Phio Pharmaceuticals' return on equity of -87.41% beat Aptevo Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Aptevo TherapeuticsN/A -201.49% -119.21%
Phio Pharmaceuticals N/A -87.41%-79.76%

Phio Pharmaceuticals is trading at a lower price-to-earnings ratio than Aptevo Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aptevo TherapeuticsN/AN/A-$25.97M-$51.83N/A
Phio PharmaceuticalsN/AN/A-$8.70M-$1.29N/A

Summary

Phio Pharmaceuticals beats Aptevo Therapeutics on 10 of the 13 factors compared between the two stocks.

Get Aptevo Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for APVO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

APVO vs. The Competition

Export
MetricAptevo TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$3.24M$3.93B$7.26B$13.30B
Dividend YieldN/A3.64%2.52%22.58%
P/E Ratio-0.0313.55274.9926.14
Price / SalesN/A1,209.42582.8587.88
Price / CashN/A119.4976.9653.71
Price / Book0.1017.1711.226.33
Net Income-$25.97M-$22.69M$3.50B$382.15M
7 Day Performance1.70%-1.34%-0.89%-1.40%
1 Month Performance-2.19%-8.45%-4.42%-3.47%
1 Year Performance-93.67%14.02%7.03%1.18%

Aptevo Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
APVO
Aptevo Therapeutics
1.1092 of 5 stars		$1.79
-0.6%		N/A-94.3%$3.24MN/AN/A33
BIVI
BioVie
1.2564 of 5 stars		$1.46
-0.7%		N/A-28.7%$12.68MN/AN/A13
PLUR
Pluri
0.8332 of 5 stars		$1.01
-1.9%		N/A-78.7%$12.47M$1.02MN/A113
VTGN
VistaGen Therapeutics
2.253 of 5 stars		$0.28
-0.6%		$0.95
+238.1%		-94.4%$12.47M$1.27MN/A41
BLRX
BioLineRx
0.5506 of 5 stars		$2.37
+0.9%		N/A-46.9%$11.49M$1.18MN/A24

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:APVO) was last updated on 10/10/2026 by MarketBeat.com Staff.
From Our Partners
This free guide explains options the way they should be taught
Most options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...
Base Camp Trading | Sponsoredtc pixel
This high yielding “gold annuity” is starting to move…
Garrett Goggin, a 20+ year gold analyst, has called major moves before: Montage Gold up 2,567%, G2 Goldfields ...
Golden Portfolio | Sponsoredtc pixel
A simple options setup that cuts through the noise
Ian Cooper says most options traders overcomplicate the process, juggling countless indicators, strategies, an...
TradeWins | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
New Chip takes minutes, not days
George Gilder believes today's AI data centers could become tomorrow's typewriters - replaced by a single wafe...
Eagle Publishing | Sponsoredtc pixel
A letter from Shannon Stansberry
Porter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...
Porter & Company | Sponsoredtc pixel
The only 5 stocks that matter
SpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO...
TradeSmith | Sponsoredtc pixel
Tech expert smashes iPhone with golf club
Twenty years ago, Josh Baylin told Congress the iPhone was coming, three years before it launched. A $1,500 be...
Stansberry Research | Sponsoredtc pixel